@WanjinH

A simple man finding his ways in a complex world

 Singapore
Joined July 2016
  • Tweets3K
  • Following523
  • Followers496
77Media
Novartis Cuts 6 Early Cancer Candidates, Adds 2 to Refine Oncology Strategy biospace.com/business/novart…

Novartis Cuts 6 Early Cancer Candidates, Adds 2 to Refine Oncology Strategy

Despite the Phase 1 cull, CEO Vas Narasimhan on Wednesday maintained that Novartis continues to invest in its early-stage pipeline, looking for deals in the “sub-$2-billion range.”

biospace.com
73
Makary Blasts ‘Illegal Copycat Drugs’ as Hims Launches Compounded Wegovy Pill biospace.com/business/makary…

Makary Blasts ‘Illegal Copycat Drugs’ as Hims Launches Compounded Wegovy Pill

Novo Nordisk has also spoken out strongly against Hims & Hers' compounded Wegovy pill, with CEO Maziar Mike Doustdar telling investors the knockoff version is a waste of money.

biospace.com
79
Lilly’s GLP-1s Mounjaro, Zepbound Push Revenue up 46% in Q4 biospace.com/business/lillys…

Lilly’s GLP-1s Mounjaro, Zepbound Push Revenue up 46% in Q4

Mounjaro and Zepbound combined for $11.7 billion in the fourth quarter, which beat analyst consensus of $10.6 billion.

biospace.com
53
Pfizer’s First Weight-Loss Data After Metsera Buy ‘Look Competitive’ biospace.com/drug-developmen…

Pfizer’s First Weight-Loss Data After Metsera Buy ‘Look Competitive’

With data from a mid-stage trial showing weight loss of up to 12.3% at 28 weeks in patients treated with PF’3944, "Pfizer is moving full speed into obesity clinical development,” BMO Capital Markets...

biospace.com
37
BioNTech’s Multi-Modality Play Outpaces Moderna’s mRNA-Focused Pipeline biospace.com/business/bionte…

BioNTech’s Multi-Modality Play Outpaces Moderna’s mRNA-Focused Pipeline

After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.

biospace.com
50
Daiichi Sankyo Dumps Next-Gen ADC From Development Pipeline biospace.com/drug-developmen…

Daiichi Sankyo Dumps Next-Gen ADC From Development Pipeline

DS-9606 was supposed to be the first antibody-drug conjugate in Daiichi Sankyo’s line of anti-cancer assets to use a modified pyrrolobenzodiazepine payload.

biospace.com
41
Novo’s Next-Gen Obesity Drug Beats Wegovy on Blood Sugar Control in Phase III biospace.com/drug-developmen…

Novo’s Next-Gen Obesity Drug Beats Wegovy on Blood Sugar Control in Phase III

While CagriSema bested Novo Nordisk's Wegovy on blood sugar control in a late-stage trial, the next-gen weight loss drug still has not met the pharma's 25% weight loss goal.

biospace.com
51
AstraZeneca’s China Trip Yields CSPC Obesity Deal Worth $1.2B Upfront biospace.com/deals/astrazene…

AstraZeneca’s China Trip Yields CSPC Obesity Deal Worth $1.2B Upfront

The pact, which could see AstraZeneca ultimately put out $18.5 billion in milestones and sales-based payments, is centered on SYH2082, a long-acting dual agonist of the GLP-1 and GIP receptors.

biospace.com
1
31
J&J Aims for $100B in Sales, Puts Stelara Patent Cliff ‘in the Rearview Mirror' biospace.com/business/j-j-ai…

J&J Aims for $100B in Sales, Puts Stelara Patent Cliff ‘in the Rearview Mirror'

Reporting Q4 and full year earnings on Wednesday, J&J executives hailed growth across the healthcare giant’s portfolio while standing fast on its talc lawsuit and tariffs.

biospace.com
35
Novo Rises as Oral Wegovy Reaches Over 3,000 Patients in First Week of Launch biospace.com/business/novo-r…

Novo Rises as Oral Wegovy Reaches Over 3,000 Patients in First Week of Launch

Despite ushering in the current GLP-1 era, Novo Nordisk has fallen behind its chief rival Eli Lilly, which has exceeded the Danish pharma in terms of sales.

biospace.com
38
FDA Delays Decision for Lilly’s Obesity Pill Orforglipron, Other Priority Voucher Awardees: Report biospace.com/fda/fda-delays-…

FDA Delays Decision for Lilly’s Obesity Pill Orforglipron, Other Priority Voucher Awardees: Report

Target action dates for drugs sponsored by Sanofi, Boehringer Ingelheim and Disc Medicine have also been pushed back despite assurances of swift reviews under the FDA's new Commissioner’s National...

biospace.com
52
AbbVie Bets Nearly $5B on RemeGen To Vie for Position in Hot Bispecific Market biospace.com/deals/abbvie-be…

AbbVie Bets Nearly $5B on RemeGen To Vie for Position in Hot Bispecific Market

The deal, which sees AbbVie paying RemeGen $650 million upfront, gives the pharma ex-China rights to the biotech’s PD-1/VEGF bispecific antibody—a modality being targeted by companies including BMS,...

biospace.com
36
J&J Stops Mid-stage Eczema Trial as $1.25B Asset Misses Efficacy Mark biospace.com/drug-developmen…

J&J Stops Mid-stage Eczema Trial as $1.25B Asset Misses Efficacy Mark

J&J paid Numab Therapeutics $1.25 billion upfront for the asset in 2024 based on the belief that its dual mechanism of action could improve on existing therapies.

biospace.com
20
yahoo.com/news/articles/firs…

First GLP-1 weight-loss pill is now available, with pledge of abundant supply

Novo Nordisk launched the first GLP-1 weight-loss pill Monday with a pledge that manufacturing investments will enable the drugmaker to avoid the type of shortages that plagued the rollout of its...

yahoo.com
17
Lilly’s Path to $94B in Revenue Rests on Oral Obesity Market and Other 2026 Milestones biospace.com/business/lillys…

Lilly’s Path to $94B in Revenue Rests on Oral Obesity Market and Other 2026 Milestones

The fierce rivalry between Novo Nordisk and Eli Lilly is alive and well, as the two companies are expected to face off with their new obesity pills this year.

biospace.com
1
22
Novo’s Wegovy Pill Wins Obesity Approval, Securing Lead in Oral GLP-1 Race biospace.com/fda/novos-wegov…

Novo’s Wegovy Pill Wins Obesity Approval, Securing Lead in Oral GLP-1 Race

Analysts called the approval a much-needed win for Novo Nordisk, but warned that the company could struggle to grow sales once rival drugs come to market.

biospace.com
37
Trump Administration Reaches Pricing Agreements with 9 More Drugmakers biospace.com/policy/trump-ad…

Trump Administration Reaches Pricing Agreements With 9 More Drugmakers

Leerink analysts hailed the deals as a sign that President Trump “is unlikely to attack the industry in 2026.”

biospace.com
20
BMS Forges $1B+ Antibody Alliance With Chinese Firm Harbour biospace.com/deals/bms-forge…

BMS Forges $1B+ Antibody Alliance With Chinese Firm Harbour

BMS is Harbour’s second powerhouse partner this year after the Chinese biotech signed a potential $4.68 billion deal with AstraZeneca in March.

biospace.com
1
129
Zealand Bets up to $2.5B in Metabolic Pact With Chinese Biotech biospace.com/business/zealan…

Zealand Bets up to $2.5B in Metabolic Pact With Chinese Biotech

Also on Thursday, Zealand held its Capital Markets Day in London, outlining the strategy for its weight management franchise in the near-term, including launching five products by 2030.

biospace.com
35
Lilly’s Retatrutide Scores Triple Trial Triumph With 26% Weight Loss, But New Safety Signal Emerges biospace.com/drug-developmen…

Lilly’s Retatrutide Scores Triple Trial Triumph With 26% Weight Loss, But New Safety Signal Emerges

Analysts were hoping for a safety profile similar to what was achieved in Phase II but an abnormal sense of touch, called dysesthesia, has emerged in the late-stage TRIUMPH-4 trial.

biospace.com
1
74
Load more